NNVC logo

NanoViricides, Inc.

NNVC
Healthcare|Biotechnology|US
$1.32
+0.03 (+2.33%)
DCF Value
$0.12
Tangible Book / Share
$0.41
Cash / Share
$0.14
Financing Filings (last 12 months)
14
Shelf registrations / offering prospectuses — latest Oct 21, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (0)

No upcoming completion dates found in active trials.

Recent Press Releases

NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials
Oct 20, 2026 · Accesswire
Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides
Oct 13, 2026 · Accesswire
NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026
Oct 6, 2026 · Accesswire
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
Oct 5, 2026 · Accesswire
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
Sep 29, 2026 · Accesswire
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
Sep 28, 2026 · Accesswire
Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
Sep 23, 2026 · Accesswire
Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in 
DR Congo with 48% Crude Fatality Rate, Says NanoViricides
Sep 15, 2026 · Accesswire
Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo
Sep 8, 2026 · Accesswire
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles
Aug 31, 2026 · Accesswire

SEC Filings (41)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 21, 2026424B5Offering prospectusDocumentIndex
Oct 8, 2026DEF 14AProxy / shareholder voteDocumentIndex
Sep 29, 20268-KMaterial eventDocumentIndex
Sep 28, 202610-KAnnual reportDocumentIndex
Sep 3, 2026424B3Offering prospectusDocumentIndex
Aug 31, 2026EFFECTDocumentIndex
Aug 21, 2026S-3Shelf registrationDocumentIndex
Jul 30, 20268-KMaterial eventDocumentIndex
Jul 27, 2026424B5Offering prospectusDocumentIndex
Jul 27, 2026424B5Offering prospectusDocumentIndex
Jul 17, 20268-KMaterial eventDocumentIndex
Jul 17, 2026424B5Offering prospectusDocumentIndex
Jul 1, 2026424B3Offering prospectusDocumentIndex
Jun 26, 2026EFFECTDocumentIndex
Jun 22, 2026DEL AMDocumentIndex
Jun 17, 2026DEL AMDocumentIndex
Jun 15, 2026EFFECTDocumentIndex
Jun 15, 2026S-3Shelf registrationDocumentIndex
Jun 5, 2026S-3Shelf registrationDocumentIndex
May 21, 20268-KMaterial eventDocumentIndex
May 20, 20268-KMaterial eventDocumentIndex
May 18, 2026424B5Offering prospectusDocumentIndex
May 15, 202610-QQuarterly reportDocumentIndex
Feb 25, 2026DDocumentIndex
Feb 17, 202610-QQuarterly reportDocumentIndex
Dec 30, 2025424B3Offering prospectusDocumentIndex
Dec 19, 2025EFFECTDocumentIndex
Dec 16, 2025DEL AMDocumentIndex
Dec 15, 2025S-3Shelf registrationDocumentIndex
Nov 26, 20258-KMaterial eventDocumentIndex
Nov 14, 20258-KMaterial eventDocumentIndex
Nov 14, 202510-QQuarterly reportDocumentIndex
Nov 12, 2025424B5Offering prospectusDocumentIndex
Nov 12, 2025424B5Offering prospectusDocumentIndex
Oct 8, 2025DEF 14AProxy / shareholder voteDocumentIndex
Oct 1, 20258-KMaterial eventDocumentIndex
Sep 29, 202510-KAnnual reportDocumentIndex
May 15, 202510-QQuarterly reportDocumentIndex
Feb 14, 202510-QQuarterly reportDocumentIndex
Dec 12, 20248-KMaterial eventDocumentIndex